Neurizon Therapeutics マネジメント

マネジメント基準チェック /14

Neurizon Therapeuticsの CEO はMichael Thurnで、 May2024年に任命され、の在任期間は 1 年未満です。の年間総報酬はA$ 415.11Kで、 69.4%給与と30.6%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.58%を直接所有しており、その価値はA$ 536.00K 。経営陣と取締役会の平均在任期間はそれぞれ0.5年と0.5年です。

主要情報

Michael Thurn

最高経営責任者

AU$415.1k

報酬総額

CEO給与比率	69.4%
CEO在任期間	less than a year
CEOの所有権	0.6%
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	less than a year

経営陣の近況

Recent updates

CEO報酬分析

Neurizon Therapeutics の収益と比較して、Michael Thurn の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	AU$415k	AU$288k	-AU$9m

報酬と市場: Michaelの総報酬 ($USD 269.76K ) は、 Australian市場 ($USD 297.81K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Michaelの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Michael Thurn

less than a year

在職期間

AU$415,107

報酬

Dr. Michael Thurn, Ph D., serves as Managing Director, CEO and Director of PharmAust Limit since May 31, 2024. He was Chief Executive Officer of Neurizon Therapeutics Limited (formerly known as PharmAust L...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Michael Thurn	MD, CEO & Director	less than a year	AU$415.11k	0.58% A$ 536.0k
John Clark	Chief Operating Officer	less than a year	AU$153.58k	0.13% A$ 118.7k
Nicky Wallis	Chief Scientific Officer	less than a year	AU$26.16k	データなし
Fiona Milner	General Manager of Epichem Pty Ltd	2.4yrs	AU$26.69k	データなし
Gary Pitt	Head of Chemistry	no data	データなし	データなし
James Rixson	Head of Production	no data	データなし	データなし
Herbert Brinkman	Head of Manufacturing	less than a year	データなし	データなし
Stefan Ross	Company Secretary	less than a year	データなし	データなし

0.5yrs

平均在職期間

経験豊富な経営陣: NUZの経営陣は経験豊富とはみなされません ( 0.5年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Michael Thurn	MD, CEO & Director	less than a year	AU$415.11k	0.58% A$ 536.0k
Kathryn MacFarlane	Director	less than a year	AU$3.13k	0.054% A$ 50.0k
Christian Schirvel	Veterinary Clinical Advisory Board Member	7.1yrs	データなし	データなし
Angela Frimberger	Veterinary Clinical Advisory Board Chair	7.1yrs	データなし	データなし
Barbara Kitchell	Veterinary Advisory Board Member	6.9yrs	データなし	データなし
Marcus Hughes	Director	less than a year	AU$10.80k	2.97% A$ 2.7m
Sergio Duchini	Non-Executive Chairman	less than a year	AU$9.38k	0.27% A$ 250.0k

0.5yrs

平均在職期間

経験豊富なボード: NUZの取締役会は経験豊富ではない ( 0.5年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Neurizon Therapeutics マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

PharmAust Limited, Annual General Meeting, Sep 30, 2024

PharmAust Limited, Annual General Meeting, Nov 20, 2023

PharmAust Limited Announces Executive Changes

PharmAust Limited Appoints Roger Aston as Non-Executive Chairman, Effective 1 September 2023

No independent directors

PharmAust Limited, Annual General Meeting, Nov 10, 2022

Recent updates

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

PharmAust Limited, Annual General Meeting, Sep 30, 2024

PharmAust Limited has filed a Follow-on Equity Offering.

PharmAust Limited has completed a Follow-on Equity Offering in the amount of AUD 3.459 million.

PharmAust Limited has announced a Derivatives Offering in the amount of AUD 39.612456 million.

PharmAust Limited, Annual General Meeting, Nov 20, 2023

Full year 2023 earnings released: AU$0.019 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

PharmAust Limited Announces Executive Changes

PharmAust Limited Appoints Roger Aston as Non-Executive Chairman, Effective 1 September 2023

First half 2023 earnings released: EPS: AU$0 (vs AU$0.004 loss in 1H 2022)

PharmAust Limited Progresses to Elevated Doses in MND Patients

PharmAust Limited Completes First Cohort of Six Patients in Its Phase 1/2 Clinical Trial of Lead Drug Candidate Monepantel in Motor Neurone Disease/Amyotrophic Lateral Sclerosis

PharmAust Limited Announces MND Trial Completes Enrolment of First Patient Cohort

No independent directors

PharmAust Limited, Annual General Meeting, Nov 10, 2022

PharmAust Limited Recruits First Pet Dog with B Cell Lymphoma in US Canine Phase 2 Trial Assessing the Efficacy of Monepantel Treatment

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.004 loss in FY 2021)

Pharmaust Updates on Canine Cancer Trials

PharmAust Limited Announces Resignation of Richard Mollard as Chief Scientific Officer

Pharmaust Limited Announces Arrival of Mpl Tablets in Melbourne for Motor Neuron Disease Clinical Trial

PharmAust Limited Expands Lymphoma Canine Trial to the USA

No independent directors

PharmAust Limited Announces Preliminary MPL Anti-Viral Leukaemia Preclinical WEHI Results

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

First half 2022 earnings: Revenues and EPS in line with analyst expectations

PharmAust Limited Provides Update on Manufacture of MPL & Tablets for Clinical Trials

Full year 2021 earnings released: AU$0.004 loss per share (vs AU$0.005 loss in FY 2020)

Pharmaust Limited Achieves Phase IIB Dog Trial's Interim Clinical Endpoints

PharmAust Receives Ethics Approval for Phase I Trial of Monepantel in Motor Neurone Disease

PharmAust Limited Announces Phase IIb Canine Trial Identifies Therapeutic Window for MPL

PharmAust Ltd Provides an Update on Phase IIb Trial Testing the Effects of Monepantel Upon Pet Owners' Dogs with Treatment Naïve B Cell Lymphoma

PharmAust Limited Announces Monepantel COVID-19 Testing in the Netherlands

PharmAust and Leiden University Medical Centre Provide Update on Monepantel COVID-19 Testing

PharmAust and Olivia Newton-John Cancer Research Institute to Continue MPL Pre-clinical Investigations

PharmAust Ltd to Commence Phase IIb Dog Cancer Trial

PharmAust Limited Provides an Update on Analysis at the Olivia Newton-John Cancer Research Institute Investigating the Mechanism of Action of Monepantel Upon Cancer Cells

Pharmaust Ltd, Entered into A Service Agreement with Leiden University Medical Center (Lumc) in Netherlands for Lumc to Test

Full year earnings released - AU$0.0046 loss per share

Full year earnings released - AU$0.0046 loss per share

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

マネジメント基準チェック /14